CAS databases provide millions of journal article references from more than 10,000 major scientific journals worldwide, patent and patent family references from 63 patent authorities
around the world, and other reputable web sources.
The following patent record is from the CAplusSM
CAPLUS COPYRIGHT 2013 ACS
|Patent Number: ||US 8318934 |
|Title: ||A process for chiral resolution of 2-substituted 4-substituted 1,3-oxathiolanes via selective recrystallization |
|Inventor(s): ||Epa, Widanagamage Ruwansiri; Marcuccio, Sebastian Mario; Deadman, John Joseph |
|Patent Assignee(s): ||Avexa Limited, Australia |
|Source: ||PCT Int. Appl., 100pp. CODEN: PIXXD2 |
|Language: ||English |
The present invention relates to a novel process for the chiral resolution of 2-substituted 4-substituted 1,3-oxathiolanes and derivs. thereof. In particular, the invention relates to resolution via selective recrystn. of a single stereoisomer from a diastereomeric mixture of the four possible stereoisomers. prepared nucleoside analogs, e.g., 2-benzoyloxymethyl-4-(N-benzoylcytosin-1-yl)-1,3-oxathiolane. The compds. of interest are nucleoside analogs which are prepared Thus, e.g., the optically active I was first prepared by reaction of 2-benzoyloxymethyl-1,3-oxathiolane-S-oxide with N-benzoylcytosine to provide a mixture of the cis/trans relative stereoisomers (2.86:1 cis/trans ratio) which underwent selective recrystn. in methanol to provide the pure 2-(R)-benzoyloxymethyl-4-(R)-(N-benzoylcytosin-1-yl)-1,3-oxathiolane (I).
View the full-text patent here.
Note: Titles and abstracts for patent records in CAplus are routinely enhanced to better describe the claimed invention. In this example, CAS enhanced both the abstract and title using additional information found in the patent. The original title of the U.S. granted patent is Process for chiral resolution of 2-substituted 4-substituted 1,3-oxathiolanes. For the CAplus record, this title was enhanced to read A process for chiral resolution of 2-substituted 4-substituted 1,3-oxathiolanes via selective recrystallization.